Loading
In older people with acute myeloid leukaemia who were not good candidates for intensive chemotherapy, azacitidine lengthened median survival by about four months compared with the usual options and became the backbone that venetoclax was later added to.
Phase 3 trial of 488 patients aged 65 or over with newly diagnosed AML and over 30 percent marrow blasts, randomised to azacitidine or a pre-selected conventional care regimen (intensive chemotherapy, low-dose cytarabine or supportive care).
Median overall survival was 10.4 months with azacitidine against 6.5 months with conventional care, a difference that was clinically meaningful but not statistically significant in the primary analysis. One-year survival was 46.5 versus 34.2 percent.
Azacitidine became the standard low-intensity treatment for older or unfit patients with AML and the control arm for later trials; venetoclax plus azacitidine (VIALE-A) now supersedes azacitidine alone where available.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine.
Shares Blood, Acute myeloid leukaemia in older or unfit patients.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine.